Back to top

Chardan Capital Maintains Buy Rating for Krystal Biotech (KRYS) | KRYS Stock News

Chardan Capital Maintains Buy Rating for Krystal Biotech (KRYS) | KRYS Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Krystal Biotech, Inc. (KRYS)